17.04.2018 • News

Mitsui Chemicals Builds Elastomers Plant in USA

Mitsui Chemicals Builds Elastomers Plant in USA (c) Mitsui
Mitsui Chemicals Builds Elastomers Plant in USA (c) Mitsui

Mitsui Chemicals America, a wholly owned subsidiary of Japan’s Mitsui Chemicals, has announced plans to build a new production facility for its Milastomer thermoplastic olefin elastomer.

The plant, which will be Mitsui Chemicals’ fourth production base worldwide for Milastomer, will be built at the Ohio site of its US subsidiary Advanced Composites. Capacity will be 6,000 t/y and construction is scheduled to start in January 2019, with completion set for June and commercial operations to begin in October 2019.

The company said the additional capacity will address growing demand in North America. Advanced Composites will be responsible for the plant’s production while Mitsui Chemicals America will handle sales in the region. Mitsui Chemicals markets the soft resin as a substitute for vinyl chloride and vulcanized rubber. Uses include automotive parts, building gaskets, toothbrushes, golf club grips, among others.

According to Mitsui Chemicals, global demand is projected to rise, primarily for applications such as automotive interior covers, weather strips, air bag covers and steering bellows.  Demand for use in automotive interior covers is expected to expand especially in North America, it said.

The company added that it is working to further strengthen its Milastomer business and ensure a steady supply by “correctly gauging” global demand growth and expanding.

Company

Logo:

Mitsui Chemicals Europe GmbH

Oststr. 34
40211 Düsseldorf
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.